You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
濟民醫療(603222.SH)業績快報:2021年度淨利潤升2205.39%至1.47億元
格隆匯 02-22 15:49

格隆匯2月22日丨濟民醫療(603222.SH)發佈2021年度業績快報,實現營業總收入11.07億元,同比增長26.14%;歸屬於上市公司股東的淨利潤1.47億元,同比增長2205.39%;歸屬於上市公司股東的扣除非經常性損益的淨利潤1.11億元,同比增長393.82%;基本每股收益0.44元。

2021年影響經營業績的主要原因分析如下:(1)公司全資子公司聚民生物實現淨利潤15221.5萬元,較上年同期增長193.31%;(2)公司處置鄆城新友誼醫院確認投資收益約3950萬元;(3)公司控股子公司鄂州二醫院對涉及的翁雄祥、姜松發民事訴訟事項,衝回前期預提的訴訟損失約1126萬元;(4)公司對應收邵品股權回購款計提20%的減值準備,金額約2115萬元;(5)公司對鄂州二醫院商譽計提減值準備1259萬元,對交易性金融資產(前期確認的業績補償鄂州二醫院20%的股權)確認公允價值變動損益約-254萬元,二者合計影響-1513萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account